GT Biopharma, Inc. (GTBP)
GTBP Stock Price Chart
Explore GT Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze GTBP price movements and trends.
GTBP Company Profile
Discover essential business fundamentals and corporate details for GT Biopharma, Inc. (GTBP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Mar 2018
Employees
1.00
Website
https://www.gtbiopharma.comCEO
Alan Louis Urban CPA
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
GTBP Financial Timeline
Browse a chronological timeline of GT Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 19 Feb 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.38.
Earnings released on 14 Aug 2025
EPS came in at -$0.55 surpassing the estimated -$0.68 by +19.12%.
Earnings released on 15 May 2025
EPS came in at -$0.76 falling short of the estimated -$0.64 by -18.75%.
Earnings released on 21 Feb 2025
EPS came in at -$1.66 falling short of the estimated -$1.55 by -7.10%.
Earnings released on 14 Nov 2024
EPS came in at -$1.53 surpassing the estimated -$2.70 by +43.33%.
Earnings released on 14 Aug 2024
EPS came in at -$2.24 surpassing the estimated -$2.70 by +17.04%.
Earnings released on 15 May 2024
EPS came in at -$2.12 surpassing the estimated -$2.70 by +21.48%.
Earnings released on 4 Apr 2024
EPS came in at -$2.19 surpassing the estimated -$2.70 by +18.89%.
Stock split effective on 5 Feb 2024
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 1 Nov 2023
EPS came in at -$1.80 surpassing the estimated -$3.00 by +40.00%.
Earnings released on 7 Aug 2023
EPS came in at -$2.70 surpassing the estimated -$3.00 by +10.00%.
Earnings released on 15 May 2023
EPS came in at -$2.40 surpassing the estimated -$4.80 by +50.00%.
Earnings released on 30 Mar 2023
EPS came in at -$5.41 falling short of the estimated -$0.17 by -3.08K%.
Earnings released on 31 Oct 2022
EPS came in at -$6.61 falling short of the estimated -$3.30 by -100.30%.
Earnings released on 11 Aug 2022
EPS came in at -$3.00 surpassing the estimated -$5.41 by +44.55%.
Earnings released on 16 May 2022
EPS came in at -$5.11 surpassing the estimated -$6.91 by +26.05%.
Earnings released on 28 Mar 2022
EPS came in at -$15.62 falling short of the estimated -$6.31 by -147.54%.
Earnings released on 10 Nov 2021
EPS came in at -$5.11 surpassing the estimated -$6.31 by +19.02%.
Earnings released on 23 Aug 2021
EPS came in at -$4.50 surpassing the estimated -$8.41 by +46.49%.
Earnings released on 17 May 2021
EPS came in at -$54.95 falling short of the estimated -$7.51 by -631.69%.
Earnings released on 16 Apr 2021
EPS came in at -$3.39 falling short of the estimated -$0.05 by -7.43K%.
Stock split effective on 11 Feb 2021
Shares were split 1 : 17 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2020
EPS came in at -$20.43 .
GTBP Stock Performance
Access detailed GTBP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.